For the quarter ended September 2025, Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.48 billion, up 3.4% over the same period last year. EPS came in at $0.78, compared to $0.69 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $4.35 billion, representing a surprise of +3%. The company delivered an EPS surprise of +14.71%, with the consensus EPS estimate being $0.68.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Europe: $1.24 billion compared to the $1.3 billion average estimate based on five analysts. The reported number represents a change of -2.4% year over year.
- Geographic Revenue- United States: $2.48 billion versus the five-analyst average estimate of $2.25 billion. The reported number represents a year-over-year change of +11.6%.
- Geographic Revenue- International Markets: $557 million versus $592.56 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -9.1% change.
- Geographic Revenue- Europe- Respiratory products: $52 million versus $59.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -13.3% change.
- Geographic Revenue- International Markets- Generic products: $421 million versus $460.92 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.7% change.
- Geographic Revenue- International markets- AJOVY: $30 million compared to the $28.2 million average estimate based on four analysts. The reported number represents a change of +25% year over year.
- Geographic Revenue- International Markets- Other: $82 million versus the four-analyst average estimate of $83.05 million. The reported number represents a year-over-year change of -17.2%.
- Geographic Revenue- Europe- Other: $91 million versus $102.91 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -26.6% change.
- Geographic Revenue- United States- Other: $101 million versus $105.84 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -12.2% change.
- Geographic Revenue- Europe- COPAXONE: $44 million versus the four-analyst average estimate of $40.26 million. The reported number represents a year-over-year change of -17%.
- Revenue- COPAXONE- Total: $114 million versus $92.9 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -15.6% change.
- Revenue- API sales to third parties: $125 million versus $131.42 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -3.9% change.
View all Key Company Metrics for Teva Pharmaceutical Industries here>>>
Shares of Teva Pharmaceutical Industries have returned +1.9% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
